Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19?
- Published in:
- Clinical Drug Investigation, 2020, v. 40, n. 10, p. 897, doi. 10.1007/s40261-020-00963-x
- By:
- Publication type:
- Article
Works matching IS 11732563 AND DT 2020 AND VI 40 AND IP 10
Results: 9
1
2
Use of Azithromycin in COVID-19: A Cautionary Tale.
- Published in:
- 2020
- By:
- Publication type:
- Letter
3
Remifentanil Target-Controlled Infusion for Conscious Sedation in Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA): A Case Series.
- Published in:
- 2020
- By:
- Publication type:
- Letter
4
Comprehensive Pulmonary Safety Review of Inhaled Technosphere<sup>®</sup> Insulin in Patients with Diabetes Mellitus.
- Published in:
- Clinical Drug Investigation, 2020, v. 40, n. 10, p. 973, doi. 10.1007/s40261-020-00958-8
- By:
- Publication type:
- Article
5
Drug-Induced Neutropenia During Treatment of Non-Neoplastic Dermatologic Diseases: A Review.
- Published in:
- Clinical Drug Investigation, 2020, v. 40, n. 10, p. 915, doi. 10.1007/s40261-020-00956-w
- By:
- Publication type:
- Article
6
Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety.
- Published in:
- Clinical Drug Investigation, 2020, v. 40, n. 10, p. 901, doi. 10.1007/s40261-020-00955-x
- By:
- Publication type:
- Article
7
Community-Acquired Bacterial Pneumonia—Changing Epidemiology, Resistance Patterns, and Newer Antibiotics: Spotlight on Delafloxacin.
- Published in:
- Clinical Drug Investigation, 2020, v. 40, n. 10, p. 947, doi. 10.1007/s40261-020-00953-z
- By:
- Publication type:
- Article
8
The Role of Delafloxacin in Patients with Community-Acquired Bacterial Pneumonia in the Outpatient Setting: A Budget Impact Model.
- Published in:
- Clinical Drug Investigation, 2020, v. 40, n. 10, p. 961, doi. 10.1007/s40261-020-00938-y
- By:
- Publication type:
- Article
9
Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug–Drug Interactions.
- Published in:
- Clinical Drug Investigation, 2020, v. 40, n. 10, p. 927, doi. 10.1007/s40261-020-00934-2
- By:
- Publication type:
- Article